All Releases
 |
NeoPharm, Inc. Announces First Quarter 2010 Financial Results and Clinical Trial Update
Jun 11, 2010
|
15.4 KB |
|
| |
LAKE BLUFF, Ill., Jun 11, 2010 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), a publicly traded biopharmaceutical
company dedicated to the research, development and commercialization of
new and innovative therapeutic applications of drugs for cancer and
other diseases, today announced its first quarter 2010 financia...
|
|
NeoPharm Announces FDA Grant of Orphan Drug Designation for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
May 17, 2010
|
10.9 KB |
|
| |
LAKE BLUFF, Ill., May 17, 2010 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that the Office of
Orphan Products Development of the United States Food and Drug
Administration (FDA) has granted orphan-drug designation for
IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary
Fibrosi...
|
|
NeoPharm Starts Enrolling Pancreatic Cancer Patients in Phase II Trial of LE-DT
Apr 20, 2010
|
11.1 KB |
|
| |
LAKE BLUFF, Ill., Apr 20, 2010 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has started
enrolling patients in its Phase II clinical trial for liposome entrapped
docetaxel (LE-DT), as a frontline treatment of pancreatic cancer
patients with locally advanced or metastatic disease. LE-DT is a ...
|
|
NeoPharm, Inc. Announces Fourth Quarter And Full Year 2009 Financial Results
Mar 18, 2010
|
22.7 KB |
|
| |
LAKE BLUFF, Ill., Mar 18, 2010 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), a publicly traded biopharmaceutical
company dedicated to the research, development and commercialization of
new and innovative therapeutic applications of drugs for cancer and
other diseases, today announced its fourth quarter and full yea...
|
|
NeoPharm Announces Orphan Drug Application Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
Mar 10, 2010
|
11.1 KB |
|
| |
LAKE BLUFF, Ill., Mar 10, 2010 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has filed
an orphan drug application with the Office of Orphan Products
Development of the United States Food and Drug Administration (FDA) to
have Orphan Drug Designation granted to IL13-PE38QQR
(IL13-PE) f...
|
|
NeoPharm Presents the Phase II Data of Liposome-Entrapped Paclitaxel (LEP) in Patients with Metastatic Breast Cancer
Jan 6, 2010
|
12.0 KB |
|
| |
LAKE BLUFF, Ill., Jan 06, 2010 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK) today announced the results of a
Phase II clinical trial of Liposome-Entrapped Paclitaxel (LEP) an active
component of Taxol(R). This multicenter, open-label trial of LEP was
conducted at 5 centers in India.
Thirty-five subjects were enrol...
|
|
NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
Jan 4, 2010
|
11.3 KB |
|
| |
LAKE BLUFF, Ill., Jan 04, 2010 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has filed
an investigational new drug application (IND) with the U.S. Food and
Drug Administration (FDA) for IL13-PE38QQR (IL13-PE) for the treatment
of Idiopathic Pulmonary Fibrosis (IPF). IPF is the most deadly di...
|
|
NeoPharm, Inc. Announces Settlement of Dispute with Diosynth, RTP
Dec 3, 2009
|
10.5 KB |
|
| |
LAKE BLUFF, Ill., Dec 03, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has reached
a settlement agreement with Diosynth, RTP ("Diosynth"). As previously
noted, NeoPharm reported that it had entered into various contractual
arrangements with Diosynth to secure access to manufacturing ca...
|
|
NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors
Nov 17, 2009
|
12.2 KB |
|
| |
LAKE BLUFF, Ill., Nov 17, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK) today announced the results of a
Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an
active component of Taxotere(R) at a joint International Conference of the
American Association for Cancer Research (AACR), the National C...
|
|
NeoPharm Names Dr. Aquilur Rahman as President and CEO
Oct 29, 2009
|
12.0 KB |
|
| |
LAKE BLUFF, Ill., Oct 29, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK) today announced the appointment of
Dr. Aquilur Rahman to the position of President and CEO of the Company,
succeeding Laurence P. Birch, who is stepping down as President and CEO
to pursue other opportunities.
Dr. Rahman's association with...
|
|
NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment
Oct 27, 2009
|
11.0 KB |
|
| |
LAKE BLUFF, Ill., Oct 27, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK) today announced that it has
submitted a Phase II protocol to the FDA for the study of liposome
entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery
system of docetaxel, the active ingredient of Taxotere(R), for
local...
|
|
NeoPharm, Inc. Announces Third Quarter 2009 Financial Results and Clinical Trials Update
Oct 26, 2009
|
21.6 KB |
|
| |
LAKE BLUFF, Ill., Oct 26, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), today announced its third quarter
2009 financial results.
For the third quarter ended September 30, 2009, NeoPharm reported a net
loss of $1.8 million, or ($0.06) per basic and diluted share, as
compared to a net loss of $2.4 million, or ...
|
|
NeoPharm, Inc. Announces Second Quarter 2009 Financial Results and Clinical Trials Update
Jul 27, 2009
|
20.8 KB |
|
| |
LAKE BLUFF, Ill., Jul 27, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), today announced its second quarter
2009 financial results.
For the second quarter ended June 30, 2009, NeoPharm reported a net loss
of $1.9 million, or ($0.07) per basic and diluted share, as compared to
a net loss of $2.0 million, or ($0...
|
|
NeoPharm, Inc. Provides ARS Update
May 11, 2009
|
9.1 KB |
|
| |
LAKE BLUFF, Ill., May 11, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC:NEOL.PK), today provided an update on its
auction rate securities ("ARS").
On November 10, 2008, and as previously reported, NeoPharm, Inc.
("Company") accepted an offer by UBS AG ("UBS") of certain rights to
cause UBS to purchase, at a future date,...
|
|
NeoPharm, Inc. Eliminates Preferred Rights Plan
Apr 29, 2009
|
10.7 KB |
|
| |
LAKE BLUFF, Ill., Apr 29, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Pink Sheets: NEOL), today announced that its Board of
Directors has approved the termination of its preferred rights plan,
commonly known as a "poison pill." The Board's action will accelerate
the current expiration date of the preferred rights plan from July ...
|
|
NeoPharm, Inc. Announces First Quarter 2009 Financial Results and Clinical Trial Update
Apr 28, 2009
|
20.9 KB |
|
| |
LAKE BLUFF, Ill., Apr 28, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Other OTC: NEOL.PK), today announced its first quarter
2009 financial results.
For the first quarter ended March 31, 2009, NeoPharm reported a net loss
of $2.3 million, or ($0.08) per basic and diluted share, as compared to
a net loss of $1.5 million, or ($0....
|
|
NeoPharm, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Mar 4, 2009
|
21.6 KB |
|
| |
LAKE BLUFF, Ill., Mar 04, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (Pink Sheets:NEOL), today announced its fourth quarter
and full year 2008 financial results.
For the fourth quarter ended December 31, 2008, NeoPharm reported a net
loss of $2.2 million, or ($0.08) per basic and diluted share, as
compared to a net loss of $1.1...
|
|
NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Castrate Resistant Prostate Cancer
Feb 11, 2009
|
10.8 KB |
|
| |
LAKE BLUFF, Ill., Feb 11, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (NASDAQ: NEOL) today announced that it has submitted a
Phase II protocol to the FDA for the study of liposome entrapped
docetaxel (LE-DT), a novel, proprietary liposomal delivery system of
docetaxel, the active ingredient of Taxotere(R), in hormone refractory
...
|
|
NeoPharm, Inc. Reports Stock Delisted Prematurely
Feb 5, 2009
|
10.5 KB |
|
| |
LAKE BLUFF, Ill., Feb 05, 2009 (BUSINESS WIRE) -- On January 23, 2009, the Company announced that it had given notice to
The NASDAQ Stock Market ("NASDAQ") of its intention to voluntarily
delist its common stock from NASDAQ by filing a Form 25 with the
Securities and Exchange Commission on or about February 2, 2009, which
...
|
|
NeoPharm, Inc. Announces Voluntary Delisting from NASDAQ and Deregistration of Common Stock
Jan 23, 2009
|
12.4 KB |
|
| |
LAKE BLUFF, Ill., Jan 23, 2009 (BUSINESS WIRE) -- NeoPharm, Inc. (NASDAQ: NEOL) today announced that it has given formal
notice to the NASDAQ Stock Market of the Company's intention to
voluntarily delist its common stock from The NASDAQ Capital Market.
NeoPharm currently anticipates that it will file with the Securities and ...
|
|
|
= add release to Briefcase |
